Feun LG, et al. - Researchers performed a phase II trial of pasireotide ascertaining its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). In patients with advanced or metastatic HCC, pasireotide showed limited clinical benefit as second-line or third-line treatment. Inefficacy of SOM230 treatment could be predicted with low baseline insulin growth factor-1 level, and decreasing levels after treatment may be indicative of disease control.